This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mulder, W. J.M. Articles by Fayad, Z. A. Search for Related Content PubMed Articles by Mulder, W. J.M. Articles by Fayad, Z. A. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:801.)
© 2008 American Heart Association, Inc.

Editorials

Nanomedicine Captures Cardiovascular Disease

Willem J.M. Mulder; Zahi A. Fayad

From the Translational and Molecular Imaging Institute and Imaging Science Laboratories, Mount Sinai School of Medicine, New York.

Correspondence to Willem J.M. Mulder, Translational and Molecular Imaging Institute and Imaging Science Laboratories, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029. E-mail willem.mulder@mountsinai.org

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Nanomedicine, the research field that makes use of nanoparticulate agents for biomedical applications, is well established in oncology.¹ In fact, the application of nanotechnology in medicine started with, and is most prominently present in, targeted therapeutics for cancer. The initial goals included altering pharmacokinetics, increasing the percentage of injected dose to reach the tumor, accomplishing target-specific delivery and uptake therefore decreasing doses of compounds with antitumor activity.² Furthermore, nanoparticles may be used to solubilize hydrophobic or amphiphilic molecules. Many nanoparticulate formulations (eg, cytostatic agents) have been shown to exhibit increased therapeutic efficacy and diminished adverse effects, which have ultimately resulted in their clinical application.³ The most well-known nanoparticulate formulations applied are liposomes (bilayered vesicles of phospholipids) which can contain a hydrophilic payload in their lumen or an amphiphilic payload in the lipid bilayer.³ Doxil, a liposomal formulation of doxorubicin, is approved for the treatment of solid tumors in patients with breast-carcinoma metastases, and has resulted in a subsequent improvement in survival.⁴ Gene targeting to angiogenic tumor blood vessels using cationic liposomes specific for vβ3-intergin has shown efficacy in tumor bearing mice.⁵ Using this approach, apoptosis of the tumor-associated endothelium was induced by a mutant Raf gene, ultimately leading to tumor cell apoptosis and sustained regression of established primary and metastatic tumors. More recently, a synergistic approach that focuses on cutting of the blood supply of the tumor and killing tumor cells was realized using so-called nanocells, nanoparticles that contain both an angiostatic and a cytostatic drug.⁶

See accompanying article on . . . [Full Text of this Article]

Related Article:

Intramural Delivery of Rapamycin With _vβ₃-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury

Tillmann Cyrus, Huiying Zhang, John S. Allen, Todd A. Williams, Grace Hu, Shelton D. Caruthers, Samuel A. Wickline, and Gregory M. Lanza
Arterioscler Thromb Vasc Biol 2008 28: 820-826. [Abstract] [Full Text] [PDF]